Dr. Frank Kalkbrenner
Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim (BI) Venture Fund, the lead investor in Acousia. He has extensive experience in Drug Discovery and Development as well as in licensing and business development. Before joining the venture fund in 2010 Frank Kalkbrenner headed the German licensing organization of BI. Frank Kalkbrenner received his MD from the University of Berlin and did his post-doc research in the Max-Planck-Institute in Berlin before he trained in Pharmacology and Toxicology. Before moving to licensing he held several position in Research in Inflammatory and Pulmonary diseases at Schering AG and BI.
Prof. Dr. Hubert Löwenheim
Hubert Löwenheim is Chairman of the Department of Otolaryngology, Head and Neck Surgery at the School of Medicine and Health Sciences at the Carl von Ossietzky University of Oldenburg and Principal Investigator of “Regenerative Biology Group”. He has extensive experience in the field of regenerative hearing loss therapies both scientifically and clinically. He was the first describing the involvement of cell cycle regulators esp. p27Kip1 in the proliferation and differentiation of hair cells and supporting cells in the cochlea. In 1998, based on these discoveries he co-founded the company Otogene AG in Tübingen and its subsidiary Otogene Inc. in Seattle with the aim to identify an inhibitor of p27Kip1 as regenerative drug. The German company ceased its operation in 2002 but the US company has continued operations and the p27Kip1 regenerative program as Sound Pharmaceuticals Inc. until today. Hubert Löwenheim received his MD from Goethe University, Frankfurt am Main and trained in Otorhinolaryngology at the University of Tübingen. His doctoral degree from Goethe University is in auditory physiology, his Habilitation degree from Tübingen University is in auditory regenerative biology. His clinical focus is in Otology & Neurootology. He has published over 50 scientific articles in the area of hearing research.